Get the app
USHealthcare

DBV Technologies (DBVT)

US · Healthcare · Biotechnology

$12.51+6.11%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-50.4M
EPS
$-0.60
EPS estimate
$-0.12

EPS came in at -0.60 against a street estimate of -0.12 — a miss of 400.0%.

Key statistics

Market cap
$744.8M
Forward P/E
0.0
P/B
5.07
Book value
$2.71
EPS (TTM)
$-3.50
52-week high
$26.18
52-week low
$8.86
50-day MA
$14.41
200-day MA
$18.14
Beta
-0.23

Analyst view

Analysts rate DBV Technologies a hold (2 buy, 0 hold, 1 sell out of 3) with an average price target of $41.38.

Shareholding

Institutions
41.66%

Largest institutional holders

FundStake
MPM Oncology Impact Management LP5.83%
Siren, L.L.C.2.96%
Vivo Capital, LLC2.94%
Baker Bros Advisors LP2.33%
Artisan Partners Limited Partnership2.18%
ADAR1 Capital Management LLC1.61%
Perceptive Advisors LLC1.53%
Logos Global Management LP1.46%

Recent filings & reports

DocumentDate
Quarterly report · Q2 2026
DBV TECHNOLOGIES S.A. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash position: $174.9 million as of June 30, 2026 (down from $194.2 million at Decem
2026-07-16
Results announced · Q3 2026
DBV TECHNOLOGIES – H1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash position: $174.9 million as of June 30, 2026 • Funding runway: Into thi
2026-07-16
Company announcement · Q2 2026
DBV TECHNOLOGIES S.A. - 8-K SUMMARY HEADLINE NUMBERS • Company: DBV Technologies S.A., France-based biopharmaceutical company • Stock listing: Americ
2026-06-29
Board / officer change · Q2 2026
DBV TECHNOLOGIES S.A. – 8-K SUMMARY HEADLINE NUMBERS • CEO Daniel Tassé granted 4,060,000 Performance Share Units (PSUs) on June 5, 2026 • 2,900,000
2026-06-05
Charter / bylaws change · Q2 2026
DBV TECHNOLOGIES S.A. – 8-K FILING SUMMARY (JUNE 3, 2026) HEADLINE NUMBERS • Annual General Meeting held June 3, 2026 with 39 shareholder proposals
2026-06-03
Proxy statement · Q2 2026
DBV TECHNOLOGIES S.A. — PROXY STATEMENT SUMMARY --- CEO COMPENSATION • Daniel Tassé (Chief Executive Officer) received total compensation of €850,0
2026-05-11
Quarterly report · Q1 2026
DBV TECHNOLOGIES S.A. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash position: $229.2 million as of March 31, 2026 (up from $194.2 million December
2026-04-30
Annual report FY2025
DBV TECHNOLOGIES S.A. – FORM 10-K SUMMARY Fiscal Year Ended December 31, 2025 --- HEADLINE NUMBERS • Market Capitalization (as of June 30, 2025): $
2026-03-26

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for DBV Technologies — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-09-18.